Scinai Immunotherapeutics
SCNI
9 hedge funds and large institutions have $54.7K invested in Scinai Immunotherapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
4.91% less ownership
Funds ownership: 9.42% → 4.51% (-4.9%)
18% less funds holding
Funds holding: 11 → 9 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
74% less capital invested
Capital invested by funds: $213K → $54.7K (-$158K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.95K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$415 |
| 3 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
+$41 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$63.2K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$31K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.31K |
| 4 |
Millennium Management
New York
|
-$5.48K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$4 |
SCNI Hedge Fund Activity: Q2 2024 in Review
9 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2024, worth a combined $54.7K — down 74% from $213K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was RhumbLine Advisers, adding an estimated $1.95K. The largest seller was Armistice Capital, exiting entirely with an estimated $63.2K sold.
- 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2024, down from 11 in Q1 2024.
- Funds reported $54.7K of Scinai Immunotherapeutics stock for Q2 2024, down 74% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q2 2024 and 3 closed out, a net change of -2 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2024 was RhumbLine Advisers, an estimated $1.95K added.
- The largest Scinai Immunotherapeutics seller in Q2 2024 was Armistice Capital, an estimated $63.2K sold.
Based on aggregated 13F filings for Q2 2024.